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Introduction: Different sexual-function preserving surgical techniques aimed at improving voiding and sexual function in patients undergoing radical cystectomy for bladder cancer have been described. The objective of this systematic review was to determine the effect of sexual function-preserving cystectomy on functional and oncological outcomes.

Materials and Methods: Relevant databases were searched covering the time frame 2000-2015. All publications presenting data on any type of sexual function-preserving cystectomy reporting oncologic and/or functional outcomes with a minimum follow-up of one year were identified. Comparative studies including a minimum of 30 patients and single-arm case series with a minimum of 50 patients were selected. No language restrictions were applied.

Results: Out of 8,517 identified abstracts, 12 studies were eligible for inclusion. Sexual function-preserving cystectomy described included prostate-, capsule-, seminal vesicle and nerve-sparing techniques. Local recurrence ranged from 1.2-61.1% (vs 16.0-55.0% in the control group) and metastatic disease from 0-33.3% (vs 33.0%). No differences were found in comparative studies reporting oncological outcomes. Post-operative potency was significantly better in the sexual function-preserving cystectomy groups in 6 studies comparing sexual function-preserving cystectomy vs radical cystectomy (p<0.05).  No major impact on continence was found. Overall, there was moderate to high risk of bias and confounding. 









Radical cystectomy remains the standard procedure for patients with muscle-invasive bladder cancer (MIBC) or non-muscle-invasive bladder cancer (NMIBC) with either high risk of progression or following failure of intravesical therapy [1,2]. This technique is associated with significant morbidity and a high prevalence of postoperative erectile dysfunction, which may have a major impact on quality of life, especially in younger patients[3,4]. Several attempts at sexual-preserving surgery have been reported in order to minimize impact on quality of life.  A neuro-anatomical approach to radical cystoprostatectomy with preservation of sexual function was first described by Shlegel and Walsh in 1987[5]. They suggested that the main reason for postoperative ED was the injury to the pelvic nerve plexus, and proposed a modification over the standard procedure that consisted of the preservation of the cavernosal nerves. Several modifications to this technique have been described to date, aiming at improving voiding and sexual function in patients undergoing radical cystectomy for bladder cancer (BC) [6,7].
Technical variations range from complete prostate preservation to other procedures where the prostate is partly or completely removed, preserving the vasa deferentia, seminal vesicles and ejaculatory ducts[8]. There is a lack of consensus regarding the best approach from a functional perspective and different expectations regarding the results. Furthermore it is not known if such techniques have a detrimental impact on oncological control. 





1. Search strategy 
The study protocol was published in the PROSPERO database[9]. The review was performed  in line with the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statement [10] using the methods outlined in the Cochrane Handbook for Systematic Reviews[11]. The databases searched were Medline, Embase and Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews and Cochrane Health Technology Assessment databases and clinicaltrial.gov. The search strategy is available in Appendix 1. Only studies published from the year 2000 onward were included to reflect current clinical practice. The search was supplemented by hand searching the reference list of European Association of Urology (EAU) Guidelines on Bladder Cancer.  The study steering group (EAU Muscle-invasive and Metastatic Bladder Cancer Guideline Panel) provided clinical expertise and advice. Relevant trialists and organizations were contacted to identify any additional relevant articles. No language restrictions were applied. The review was commissioned by the EAU Muscle-invasive and Metastatic Bladder Cancer Guideline Panel as part of its guideline update for 2016.
Following de-duplication, all abstracts and eligible full text articles were independently screened by different reviewers (VH, ELE, JD). Any disagreements were resolved by discussion or by consulting a third independent party (SM or TL) who acted as an arbiter.
2. Types of study design included 
All study designs incorporating the relevant interventions were eligible, including Randomised Controlled Trials (RCTs), Quasi-Randomised Controlled Trials, prospective and retrospective non-randomised comparative studies (NRCSs), including studies with historical controls as control group and observational studies, and single-arm case series. Conference meeting abstracts with no subsequent full text report were excluded. For inclusion, studies needed to have a minimum follow-up of 1 year; comparative studies needed to have recruited at least 30 participants; and case series needed at least 50 participants. 
3. Types of participants 
The participant population was men with BC undergoing cystectomy (for MIBC or high risk NMIBC) with curative intent in the primary setting. Participants with up to clinical stage T4, Nx/N1, M0 were included. Neo- and/or adjuvant treatment (chemotherapy) was allowed. 
4. Types of intervention and comparator
The following interventions were included:
-	Prostate-sparing radical cystectomy: part or the whole prostate is preserved including seminal vesicles, vas deferens and neurovascular bundles.
-	Capsule-sparing radical cystectomy: the capsule or peripheral part of the prostate is preserved, however, a transurethral resection of the prostate (TURP) or adenomectomy is performed. Seminal vesicles, vas deferens and neurovascular bundles are also preserved
-	Seminal vesicle-sparing cystectomy: seminal vesicles, vas deferens and neurovascular bundles are preserved.
-	Neurovascular bundle-sparing cystectomy: the neurovascular bundles are the only tissue preserved.
A valid comparator was standard radical cystectomy (without any sexual function-preserving technique) or any of the pre-specified interventions.

5. Types of outcome measures 
 Primary outcomes were:
	Sexual function (as defined by trialists [e.g. ability to engage in sexual activity, erectile function, ejaculatory function, etc.], based on pre-operative and post-operative assessment with validated-questionnaires or self-impression reports) at 6-12 months.
	Oncological outcomes: were defined as positive margins, any local or metastatic disease recurrence, disease-free survival and overall survival at >2 years.
Secondary outcome was: 
	Continence (including need for self-catheterisation, pad usage, incontinence questionnaires, night vs day continence, etc.), measured with validated-questionnaires, number of pads or self-impression reports; measured immediately, at 6 and 12 months.
6. Assessment of risks of bias 
The risk of bias (RoB) in the included studies was assessed using the Cochrane Risk of Bias Assessment tool for RCTs[11]. A modified version of the RoB assessment tool was used in assessing NRCSs with the addition of further domains to assess risk of confounding[12]. A list of the five most important potential confounders for harm and benefit outcomes was developed a priori with clinical content experts (EAU Muscle-invasive and Metastatic Bladder Cancer Guideline Panel) [9]. The assessment of single-arm case series focussed on reporting biases and external validity[9]. This pragmatic approach is informed by the methodological literature[13,14].
7. Data analysis
A narrative synthesis was planned because of the anticipated clinical and methodological heterogeneity in included studies. Descriptive statistics were used to summarise baseline characteristics data. For continuous variables, data were summarised using mean (+/- standard deviation) and median (+/- interquartile range); for categorical variables, data were summarised using proportions. When time-to-event data were reported by authors using univariate or multivariate models (e.g. Cox regression), data were summarised as hazard ratios and 95% confidence intervals, median survival and point estimates at specific time points as appropriate. Subgroup and sensitivity analyses were also planned, if data were available, to explore the impact of clinical heterogeneity on the results[9]. 
RESULTS
EVIDENCE SYNTHESIS
1. Quantity of evidence identified
Out of 8,517 abstracts assessed, 26 articles were eligible for full text screening, and 21 articles reporting on 12 studies were included (Figure 1).

Figure 1. PRISMA flow diagram of studies identified, excluded and included

2. Characteristics of included studies 

























Table 1. Baseline characteristics of all included studies

Study ID(Author and country)	Type of study		Type of surgery	Number of patients	Median Follow-up (months)
		Recruitment period		Entire study	Intervention	Control	Intervention	Control
Jacobs 2015; USA	RCT	Prospective	2007-2011	Capsule sparingvs Nerve sparing	40	CS:20	NS:20	41	37
De Vries 2009/ Mertens 2014; Netherlands	Comparative	Retrospective (Matched pair)	1994-2006	Prostate sparingvs RC	126	63	63	76	56
Basiri 2012; Iran	Comparative	Retrospective (Matched pair)	2003-2008	Capsule sparingvs RC	50	23	27	39	35
Wang 2008; China	Comparative	Retrospective	2000- 2006	Capsule sparingvs RC	36	27	9	3-84
Moon 2005; Korea	Comparative	Retrospective	1999-2003	Capsule sparingvs RC	35	17	18	16.1(6-27)	17.9(6-44)
Vilaseca 2013; Spain	Comparative	Retrospective	2006-2009	Nerve sparingvs RC	44	11	33	21
El-Bahnasawy 2006 /Hekal 2009; Egypt	Comparative	Retrospective	2003-2005	Nerve sparingvs RC	60	30	30	38.8+19.2	42.9+26.9
Kessler 2004; Switzerland	Comparative	Retrospective	1985-2003	Nerve sparingvs RC	331	256	75	31.2 (IQR 12-72)	
Colombo 2015; Italy	Comparative	Retrospective	1997-2012	Capsule sparing vs  Seminal sparing vs Nerve sparing	90	CS:36	SS:19NS:35	58 (16–174)	CS: 141SS: 36NS: 113
Gotsadze 2008; Georgia	Single-arm case series	Retrospective	1991-2005	Prostate sparing	87	87		36.8 ± 34.6(9–161) *	
Rozet 2008; France	Single-arm case series	Retrospective	1992-2004	Capsule sparing	108	108		55 ± 3.6(3-146.2)	
Muto 2014; Italy	Single-arm case series	Retrospective	1990-2009	Capsule sparing	91	91		102(28-236)*	
IQR: intercuartilie range; CS: capsule sparing; SS: seminal sparing; NS: nerve sparing* Data expressed as mean


In the majority of cases, the open surgical approach was used. Only three studies reported that some patients underwent laparoscopic or robotic surgery[17,23,24]. The urinary diversion of choice was an orthotopic neobladder in the majority of studies. Only two studies reported heterotopic urinary diversions in less than 25% of recruited  patients[20,22].
Median follow-up ranged from 16.1-141 months, and was longer than 3 years in 9 studies[15,17,18,21,23–27], with 3 of them presenting results at a median follow-up longer than 5 years[15,24,27].
Patient selection was different across all the identified studies and is summarized in Table 2. Median age ranged from 47 to 62 years in the intervention group and from 46 to 61 years in the control group. Prostate cancer was ruled out with DRE, PSA, transrectal biopsy or biopsy of the prostatic urethra by TURP in all of the sexual function-preserving cystectomy (SPC) techniques, except in those performing nerve-sparing cystectomy where no prostatic tissue was left in place.

Table 2. Patient selection in all included studies.

Study ID	Type of surgery	INCLUSION  CRITERIA
		Tumour-free (bladder neck/ prostatic urethra)	Absence of Prostate Cancer	Organ confined disease	Normal preoperative sexual function	Age
			DRE	PSA	Biopsy (TRUS)	Biopsy (TURp)			
Jacobs 2015	Capsule sparingNerve sparing								
De Vries 2009/ Mertens 2014	Prostate sparingvs RC								
Basiri 2012	Capsule sparingvs RC								
Wang 2008									
Moon 2005									
Vilaseca 2013	Nerve sparingvs RC								
El-Bahnasawy 2006 /Hekal 2009									
Kessler 2004									
Colombo 2015	Capsule sparingSeminal sparingNerve sparing								






3. Risk of bias and confounding assessment
RoB and confounding assessments for RCT, NRCSs and case series are presented in Figures 2-4. The single RCT[23] had an overall low RoB, whilst for NRCSs, the majority of studies had high RoB across more than 50% of domains. For case series, the overall risk of bias was moderate.  

Figure 2. Risk of bias and confounding assessments for RCT 


Figure 3. Risk of bias and confounding assessments for NRCSs 







4. Comparisons of interventions results
4.1 Data from comparative studies
Oncological results
The clinical and pathological characteristics of the patients are presented in Table 3. Local recurrence after SPC was commonly defined as any urothelial cancer recurrence below the iliac bifurcation within the pelvic soft tissue and ranged from 7.9-61.1% (vs 15.9-55.0% in the control group). Metastatic recurrence was reported in only one comparative study with rates of 28.6 and 33.3% in both groups[15]. The use of neoadjuvant therapy was scarcely reported  and only two studies reported some use of adjuvant chemotherapy in this setting [15,17]. No differences were found in any of the three comparative studies reporting oncological outcomes for the prostate-, capsule- or nerve-sparing techniques (Table 4 and Figure 5).


Table 3. Oncological outcomes: Clinical and pathological characteristics of participants in all included studies

Study ID	Clinical Bladder Stage (>T2/N+)	Pathological Bladder Stage (>T2/N1)	Incidental Prostate Cancer
	Intervention	Control	p-value	Intervention	Control	p-value	Intervention	Control	p-value	GS >=8
Jacobs 2015	T2+T3: 50.0%N+:0%	T2+T3: 70.0%N+:0%	0.23	>T2: 10.0%N1:  10.0%	>T2: 20.0%N1:  25.0%	0.450.19	15.0%	40.0%	0.15	0%
De Vries 2009/ Mertens 2014	>T2: 15.9%N+: 11.1%	>T2: 23.8%N+: 11.1%	NS	>T2: 25.4%N1:  28.6%	>T2: 34.9%N1: 19.0%	NSNS	3.2%	14.2%	-	-
Basiri 2012	>T2: 17.4%N+: 0%	>T2: 3.7%N+:0%	0.31	>T2: 26.0%	>T2: 33.3%	0.51	4.3%	7.4%	0.86	0%
Wang 2008	-	-	-	>T2: 48.1%	>T2: 44.4%	>0.05	-	-	-	-
Moon 2005	>T2:0%	>T2:0%	NS	-	-	-	-	-	-	-
Vilaseca 2013	>T2:0%	>T2:0%	NS	N1: 15.9%	-	-	-	-	-	-
El-Bahnasawy 2006 /Hekal 2009	>T2:0%	>T2:0%	NS	>T2: 52.3%N1: 9.5%	>T2: 54.1%N1: 16.7%	0.420.42	-	-	-	-
Kessler 2004	N+:0%	N+:0%		>T2: 51.7%N1: 23.9%	-	-	-	-	-	-
Colombo 2015	>T2:0%	>T2:0%	NS	>T2: (CS) 8.3% N1: (CS) 2.8% 	>T2: (NS) 8.6%; (SS) 5.3%N1: (NS) 2.9%; (SS) 0%	0.5NR	 CS: 0%	NS: 17.1% SS: 15.8%	-	-
Gotsadze 2008	-			>T2: 6.9%N1:  19.5%			-			-
Rozet 2008	-			>T2: 40.7%N1:  13.9%			5.5%			-
Muto 2014	>T2:0%N+:0%			>T2: 1.1%N1:  0%			2.2%			-






Table 4. Oncological outcomes: Local recurrence and metastatic disease


Study ID	Type of surgery	Neoadyuvant chemotherapy % (n/total)	LOCAL RECURRENCE% (n/total)	METASTATIC DISEASE% (n/total)
		Intervention	Control	p-value	Intervention	Control	p-value	Intervention	Control	p-value
De Vries 2009/ Mertens 2014	Prostate sparing vs RC	17.5%(11/63)	12.7%(8/63)	-	7.9% (5/63)	15.9% (10/63)	0.1	28.6% (18/63)	33.3% (21/63)	0.4
Gotsadze 2008	Prostate sparing	-	-	-	1.2% (1/87)			8.0% (7/87)		
Basiri 2012	Capsule sparing vs RC	0	0	ns	61.1% (11/18)	55.0% (11/20)	>0.05	-	-	-
Wang 2008		0	0	ns	-	-	-	-	-	-
Moon 2005		-	-	-	-	-	-	-	-	-
Rozet 2008 	Capsule sparing	0			4.6% (5/108)			33.3% (36/108)		
Muto 2014 		-			2.2% (2/91)			6.6% (6/91)		
Jacobs 2015 (CS group)		40%(8/20)			-			-		
Colombo 2015 (CS group)		-			5.5% (2/36)			5.5% (2/36)		
Vilaseca 2013	Nerve sparing vs RC	-	-	-	18.2% (2/11)	21.2% (7/33)	0.14	-	-	-
El-Bahnasawy 2006 / Hekal 2009		0	0	ns	-	-	-	-	-	-
Kessler 2004		-	-	-	-	-	-	-	-	-
Jacobs 2015 (NS group)	Nerve sparing	50%(10/20)			-			-		
Colombo (NS group)		-			5.7% (2/35)			0% (0/35)		
RC: radical cystectomy; CS: capsule sparing; NS: nerve sparing; ns: non-significant







Two comparative studies presented results of disease-specific survival (DSS) or overall survival (OS), showing no statistically significant differences between groups for the prostate- and capsule-sparing techniques at a median follow-up of 3 to 5 years (Table 5) and one of the studies comparing two different types of intervention did not show any difference in recurrence-free survival (RFS), progression-free survival (PFS), DDS or OS between groups[23].




Table 5. Oncological outcomes: recurrence-free survival, progression-free survival, disease-specific survival and overall survival

Study ID	Type of surgery	RFS	PFS	DSS	OS
		Intervention	Control	p-value	Intervention	Control	p-value	Intervention	Control	p-value	Intervention	Control	p-value
De Vries 2009/Mertens 2014	Prostate sparing vs RC	-	-	-	-	-	-	3 yr: 77%5 yr: 66%	3 yr: 68%5 yr: 64%	p=0.6	-	-	-
Gotsadze 2008	Prostate sparing	-			-			-			-		
Basiri 2012	Capsule sparing vs RC	-	-	-	-	-	-	5yr: 35%	5yr:13%	-	5yr: 47% Median OS: 48mo	5yr: 30%Median OS: 36 mo	p>0.05
Wang 2008		-	-	-	-	-	-	-	-	-	-	-	-
Moon 2005		-	-	-	-	-	-	-	-	-	-	-	-
Rozet 2008	Capsule sparing	-			-			5yr: 71%			5yr: 67%		
Muto 2014		-			6yr CSS: 90.2%- 93.3%	-	-	6yr: 88.5%-93.3%	-	-	6yr: 89.6%-93.3%	-	-
Vilaseca 2013	Nerve sparing vs RC	-	-	-	-	-	-	-	-	-	-	-	-
El-Bahnasawy 2006 / Hekal 2009		-	-	-	-	-	-	-	-	-	-	-	-
Kessler 2004		-	-	-	-	-	-	-	-	-	-	-	-
Jacobs 2015	Capsule vs Nv sparing	-	-	p>0.05	-	-	p>0.05	-	-	-	-	-	p >0.05
Colombo 2015	Capsule vs Seminal vs Nerve sparing	-	-	-	-	-	-	-	-	-	-	-	-




Sexual and functional results
Sexual outcomes were evaluated in 832 patients (699 in the intervention group and 133 in the control group) using validated-questionnaires (International Index Erectile Function; Erection Hardness Score; Bladder cancer Index;) in eight studies [7,17,20,22–25,27] and self-impression reports in seven. Four studies described some type of ejaculation outcome, such as antegrade or retrograde ejaculation[16,17,25,27] 
Postoperative potency was significantly better than standard cystectomy in the SPC groups in 6 studies comparing SPC vs RC (p<0.05), ranging 89.7%, 58.0-93.8% and 77.0-78.8% for prostate, capsule or nerve-sparing techniques, respectively (Table 6 and Figure 6). Antegrade ejaculation was reported in 7-35.5% in two studies and 63.2%-100% reported retrograde ejaculation when addressed. 
In the two studies comparing different sexual sparing techniques, only Colombo found differences in favour of capsule-sparing cystectomy or seminal-sparing cystectomy over the nerve-sparing cystectomy. 
Table 6. Sexual function results


Study ID	Postoperative sexual function assessment	Sexual outcomes-potency
	Time frame (months)	Questionnaire	Self-impression	n evaluated(Intervention vs Control)	Intervention	Control	p	Treatment ED
PROSTATE SPARING
De Vries 2009/ Mertens 2014	NA	No	Yes	87 (Int only)	89.7%	-	-	NA
Gotsadze 2008	NA	Yes, NR	No	54 (Int only)	79.6%	-	-	NA
CAPSULE SPARING
Basiri 2012	6	Yes, IIEF-5	Yes	24 (12 vs 12)	58.0%	0%	0.002	NA
Wang 2008	6	No	Yes	30 (23 vs 7)	83.0%	43.0%	<0.05	NA
Moon 2005	3-12	No	Yes	34 (16 vs 18)	93.8%	0%	<0.001	PDE-5
Rozet 2008 	NA	-	-	-	-	-	-	-
Muto 2014 	6	Yes, IIEF	No	91	95-100%	-	-	1.0% PDE-53.4% PG  (alprostadil)
Jacobs (CS group)	12	Yes, BCI	Yes	20	50.0%	-	-	-
Colombo (CS group)	24	Yes, IIEF-5	Yes	36	91.6%	-	-	-
NERVE SPARING
Vilaseca 2013	NR	Yes, EHS	No	30 (9-21)	77.8%	4.5%	<0.001	100% Intervention, 23.0% control (PDE-5)
El-Bahnasawy 2006 / Hekal 2009	12	Yes, IIEF-5	No	21	78.8%	0%	<0.05	21.0% PDE-5
Kessler 2004 	3-24	Yes, NR	Yes	331 (256-75)	77.0%	-	<0.001	8.0% PDE-5, 16.0% PG
Jacobs (NS group)	12	Yes, BCI	Yes	20	45.0%	-	-	-
Colombo (NS group)	24	Yes, IIEF-5	Yes	35	28.6%	-	-	-
INTERVENTION vs INTERVENTION
Jacobs 2015Capsule sparingNerve sparing	12	Yes, BCI	Yes	40 (20-20)	50.0%45.0%	-	0.06	55.0% PDE-5
Colombo 2015Capsule sparing Nerve sparingSeminal Sparing	24	Yes, IIEF-5	Yes	90 CS:36NS:35SS:19	91.6%28.6%84.2%	-	<0.001	19.4% PDE-554.2% PDE-531.0% PDE-5




Figure 6. Forest plot for sexual function results

Functional results were evaluated in 917 patients (720 in the intervention group and 197 in the control group). Incontinence was defined as the use of 1 or more pads in the majority of studies. The type of measurement used to evaluate continence varied across all studies. Number of pads was used in 6 studies [16,17,19–21,24] and self-impression was used in 7 studies, only 1 study [20] used pad-test for continence evaluation and 2 studies used voiding diaries [21,27].






Table 7. Continence results
Study ID	Postoperative continence function assessment	Urinary outcomes-Continence
	Time frame (months)	Measurements	n evaluated (Intervention-Control)	Day-time Intervention	Day-time Control	p	Night-time Intervention	Night-time Control	p
PROSTATE SPARING
De Vries 2009/Mertens 2014	NA	Nº pads, self-impression, PVR	105	96.0%	-		82.0%	-	
Gotsadze 2008	NA	-	85	100%	-		96.0%	-	
CAPSULE SPARING
Basiri 2012	6	Nº pads, self-impression	29 (16-13)	94.0%	92.0%	>0.05	81.0%	62.0%	>0.05
Wang 2008	6	Self-impression	36 (27-9)	88.9%	33.3%	<0.05	88.9%	33.3%	<0.05
Moon 2005	1-9	Nº pads	34 (16-18)	100%	94.0%	0.52	81.0%	50.0%	0.06
Rozet 2008 	NA	-	-	-	-	-	-	-	-
Muto 2014 	NA	Self-impression, voiding diary	91 (61-30)	95.0-100%	-	0.2	31.0-50.0%	-	0.07
Jacobs 2015 (CS group)	12	Self-impression, BCI questionnaire	20	BCI reduction*:13±30			NA		
Colombo 2015 (CS group)	48	Nº pads	-	94.4%			77.8%		
NERVE SPARING
Vilaseca 2013	NA	Nº pads, pad-test	33 (11-22)	91.0%	91.0%	0.99	55.0%	50.0%	0.81
El-Bahnasawy 2006 / Hekal 2009	12	Nº pads, self-impression, voiding diary	60 (30-30)	97.0%	93.0%	NA	70.0%	63.0%	>0.05
Kessler 2004 	12	Self-impression	331 (256-75)	92.0%		0.02	67.0%	-	0.86
Jacobs 2015 (NS group)	12	Self-impression, BCI questionnaire	20	BCI reduction*:28±33	-	-	-	-	-
Colombo 2015 (NS group)	48	Nº pads	-	82.9%	-	-	62.9%	-	-
INTERVENTION VS INTERVENTION
Jacobs 2015 (RCT)Capsule sparingNerve sparing	12	Self-impression, BCI questionnaire	34	BCI reduction*: 13±3028±33	- 	0.1	NA	-	
Colombo 2015Capsule sparingNerve sparingSeminal sparing	48	Nº pads	79	94.4%82.9%89.5%		0.3	77.8%62.9%63.2%	-	0.05






Figure 7. Forest plot for continence results

In the two studies comparing different SPC techniques, no differences were observed for day-time continence, and only Colombo found differences in favour of capsule-sparing cystectomy in night-time continence.
Only one comparative study (Basiri 2012) presented data of patients dependent on clean intermittent catheterization in both groups. In that study, there were differences in favour of the standard cystectomy (31% in the capsule sparing group vs 8% in the control group). The rest of the studies, presented rates of CIC for the intervention group that ranged from 2% to 31%.

4.2 Data from single-arm case series
The three single-arm case series included in this review[25–27] presented oncological results that were slightly better than in comparative studies in terms of local recurrence (1.2-4.6%), with similar rates of metastatic recurrence (6.6-33.3%). DSS and OS at a median time of 5 and 6 years were also better studies for two of the studies[26,27]. 




The review found that sexual outcomes in terms of postoperative potency were significantly better in the SPC groups compared with standard radical cystectomy in all comparative studies that reported this outcome[7,17–20,22]. In addition, large case series of SPC showed potency rates of 79-100%[25–27]. In terms of studies comparing different sparing techniques, conflicting findings were found. Jacobs et al[23], the only RCT included in this review, compared capsule-sparing vs nerve-sparing cystectomy and found potency rates in both groups were not significantly different (50% vs 40%). Colombo et al[24] analysed three different techniques, finding capsule-sparing cystectomy and seminal-sparing cystectomy to be superior over nerve-sparing cystectomy; however, no real conclusions can be drawn due to the limited number of patients included in the study and its retrospective design.
It has been postulated that sparing therapies could have an impact on continence outcome in series with continent urinary diversion. Large cystectomy case series with long follow-up have reported diurnal incontinence rates of 8-10% and nocturnal incontinence of 20-30%[28,29]. In this review, continence outcomes were similar in patients submitted to standard cystectomy or to any kind of preserving technique. Only two studies showed an improvement in functional outcomes in favour of the sexual preserving techniques, but considering the low number of patients[18] and the retrospective study design[7], as well as the wide confidence intervals, these results should be interpreted with caution. When comparing sparing techniques, Jacobs et al’s RCT[23], with a primary objective of continence-outcome assessment, showed no differences between capsule-sparing vs nerve-sparing cystectomy.
Finally, there has been a concern that oncological outcomes could be compromised by sparing techniques with an increased risk of widespread unusual metastases [30,31]Local recurrence was <20% in all studies except one [17] with a median follow-up period of 21 to 102 months, with no significant differences between the prostate-, capsule- or nerve-sparing techniques. Basiri et al[17] reported higher rates of local recurrence (61% vs 55%), with no significant differences between groups. This higher recurrence rate in both groups in the study compared with the other studies may reflect clinical heterogeneity in terms of differences in patient and disease characteristics between the studies. For metastatic disease, only one comparative study[15] measured the outcome, with no differences found between groups (29 vs 33% for prostate-sparing cystectomy vs radical cystectomy, respectively). The other studies reporting metastatic recurrence were case series showing rates of  0% for nerve-sparing technique[24] and 5-33% for prostate or capsule sparing techniques[24–27]. In seven studies, the oncological outcomes were presented as RFS, PFS, DSS or OS. No differences were found in the two studies comparing prostate- or capsule-sparing cystectomy vs radical cystectomy[15,17], nor in the studies comparing the different SPC techniques[23,24]. In summary, none of the comparative studies found any differences in oncological outcomes between SPC vs radical cystectomy, or between the different sparing techniques, regardless of which measure of oncological effectiveness was reported, or the time point of measurement.
Implications for clinical practice and further research
Although sexual preserving techniques were first described in the 1980s[5], there are major uncertainties and unanswered questions, including the ideal candidates for these procedures, the most effective technique, the magnitude and nature of functional benefits, and if oncological outcomes are compromised[30,31]. There is a lack of clear guidelines on the topic.  This systematic review was hampered by heterogeneity in the outcomes reported, and lack of standardization in the definitions of outcomes, the tools used to measure the functional outcomes, and the time point at which these outcomes are measured. The field of nerve sparing bladder cancer surgery would benefit form a core outcome set[32] and well-designed RCTs[33]. Nonetheless, the present study represents the first systematic review addressing the effectiveness of different sexual preserving cystectomy techniques in men.   	
Considering all the points previously discussed, the overall oncological results appear to be acceptable, but selection of patients is of paramount importance. Although patient selection was different across all the studies, in the majority, the authors stated some oncological inclusion criteria (i.e. tumour-free in the bladder neck and prostatic urethra, or the presence of organ confined disease) and some functional criteria as a normal preoperative sexual function, or the age of the patients. A sexual-preserving cystectomy could be offered to motivated men aiming to preserve their sexual function with organ-confined disease and the absence of tumour in the bladder neck, prostate or prostatic urethra. Magnetic resonance imaging can be considered in the preoperative assessment in order to improve local staging[1]. Prior to surgery, and mainly for those techniques where some prostate tissue is left in place, any tumour at the prostate, prostatic urethra or bladder neck should be ruled out with preoperative PSA, TURP or transrectal biopsy.
Based on the results of this systematic review, none of the SPC techniques (Prostate/Capsule/Nerve Sparing) can be recommended over the others due to the lack of any clear superiority, in the limited number of studies comparing them. 
The impact of new techniques and approaches such as robotic surgery on outcomes remains unknown[34–36], and only a small number of patients included in this review were operated on with a robot-assisted device. Finally, all of the described preserving techniques have a considerable learning curve, which could hinder the implementation of the procedures even in specialist centres.
Strengths and limitations
The main strength of the review is the robust, reproducible and transparent methodology based on Cochrane Review principles. The review elements, including research questions, participants, interventions, comparison and outcomes (PICO), search strategy, and study inclusion and exclusion criteria were developed in conjunction with the EAU MIBC Guideline Panel which is a multi-disciplinary panel of expert urologists, oncologists, pathologists, radiologists, methodologists and patient representative. The quality of evidence appraisal was based on meticulous risk of bias and confounding assessment using standardized tools. The findings of this review were incorporated into the panel’s guideline update for 2016. The main limitations include the clinical and methodological heterogeneity present across studies, such that it is difficult to be certain how comparable the results of studies are, and to determine the impact of important confounders on the outcomes. In addition, the majority of studies were small, retrospective non-randomised studies with moderate to high risks of bias and confounding, thereby compromising the overall quality of the evidence base.  In order to minimize these limitations, studies with small numbers of participants or short follow-up were excluded. 

CONCLUSION
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